Invited Paper

Management of Malignant Pleural Mesothelioma


  • Mustafa Gürbüz
  • Güngör Utkan

Received Date: 28.12.2018 Accepted Date: 16.04.2019 J Ankara Univ Fac Med 2019;72(1):24-28

Malignant mesothelioma (MM) arises from mesothelial surfaces of the pleural cavity, peritoneal cavity, tunica vaginalis, or pericardium. MM is a rare and insidious neoplasm with a poor prognosis. Malignant pleural mesothelioma (MPM) is the most common type and typically arises from the mesothelial surfaces of the pleural cavity. MPM can be difficult to treat because most patients have advanced disease at presentation. The median survival of patients is between 6 and 18 months. However, carefully selected patients with localized disease who receive aggressive multimodality therapy have relatively prolonged survival. In this review, we aimed to evaluate the results of surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy studies to improve survival in MPM.

Keywords: Malignant Pleural Mesothelioma, Treatment, Chemotherapy, Targeted Therapy, Immunotherapy

Full Text (Turkish)